ADENOSCAN
LOE ApproachingNDAINTRAVENOUSSOLUTION
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADENOSCAN (adenosine) is an intravenous small-molecule diagnostic agent approved in 1995 for evaluating coronary artery disease by inducing pharmacologic stress similar to exercise. It works by activating adenosine receptors to increase coronary blood flow, allowing visualization of perfusion defects during cardiac imaging. The drug is administered as an IV solution during stress testing procedures.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); diminishing commercial team investment likely.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
Started Mar 2012
48 enrolled
Coronary Artery Disease
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Started Apr 2004
787 enrolled
Coronary Artery Disease
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Started Oct 2003
1,231 enrolled
Coronary Artery Disease
Career Relevance
Zero linked job postings reflect the product's mature, declining-revenue stage; career opportunities are limited and primarily maintenance-focused. Roles available are typically in field sales, hospital account management, and medical education rather than strategic growth positions.
Worked on ADENOSCAN at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.